VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Up 1.3 %

VBI Vaccines stock opened at $0.59 on Friday. The stock has a market cap of $16.92 million, a price-to-earnings ratio of -0.05 and a beta of 1.90. The business has a 50-day simple moving average of $0.61 and a 200 day simple moving average of $0.61. VBI Vaccines has a 52 week low of $0.45 and a 52 week high of $3.47.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.